Explore key emerging trends in bioequivalence (BE) studies transforming generic drug development. Discover how ICH M13A global harmonization, model-integrated evidence (PBPK/MBBE), advanced bioanalytics, and strict data integrity standards streamline regulatory pathways for complex generics. Learn how Zenovel helps pharmaceutical companies optimize BE trial designs, minimize study variations, and accelerate FDA and EMA market approvals.
